Company / Working Capital per Share
Corvus Pharmaceuticals, Inc. Working Capital per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital per Share
$0.31
FY2024
5-year range
$0.31 / $1.47
FY2020-FY2024
Trend
-29.0%
vs FY2023
Sector context
#202 of 212
Health Care
What the data says
Among 212 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 5% for working capital per share. Working Capital per Share has declined for 3 consecutive years, from $1.47 in FY2021 to $0.31 in FY2024.
Based on SEC 10-K filings.
0.31 in FY2024 with a 5-year CAGR of -33.3%.
Declined from $0.71 to $0.31 over the past 2 years.
Health Care sector context is included.
Working Capital per Share over time
Growth rates
- 3-Year CAGR
- -40.4%
- 5-Year CAGR
- -33.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 212This company $0.31 Sector average $117.56
▼
-99.7% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s working capital per share has declined for 3 consecutive years.
- In FY2024, working capital per share decreased 29.0% year-over-year.
- Ranks #202 out of 212 companies in the Health Care sector.
- Peak working capital per share was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working Capital per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.31 | -29.0% |
| FY2023 | $0.44 | -37.9% |
| FY2022 | $0.71 | -52.0% |
| FY2021 | $1.47 | +30.8% |
| FY2020 | $1.13 | -52.2% |
| FY2019 | $2.36 | -40.3% |
| FY2018 | $3.95 | -1.7% |
| FY2017 | $4.02 | -52.4% |
| FY2016 | $8.44 | -96.6% |
| FY2015 | $247.81 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026